文献速递关节外科创伤骨科

氨甲环酸对接受全关节置换术的终末期肾病患者安全吗?

Is Tranexamic Acid Safe for Patients Who Have End-Stage Renal Disease Undergoing Total Joint Arthroplasty?
PubMed 文献 · J Arthroplasty · 2024-11-17

该回顾性图表综述纳入2011年1月至2024年2月间123例终末期肾病(ESRD)患者,比较接受与未接受氨甲环酸(TXA)者围手术期肌酐变化、急性肾损伤及90天急诊、再入院和死亡率等结局。结果显示各队列中TXA组与非TXA组上述结局均无显著差异,作者认为TXA不应在此人群中被视为禁忌。

要点

  • 在ESRD患者中,TXA组与非TXA组术后肌酐变化及急性肾损伤发生率无显著差异(P值均≥0.159)。
  • TXA组内不同剂量或给药途径的肌酐变化无显著差异(P值分别≥0.428和≥0.256)。
  • 90天急诊就诊、再入院及死亡率在TXA组与非TXA组间无统计学显著差异(P值均≥0.055)。

核心结论

  • 作者认为,对因骨折接受全关节置换术或半髋置换术的ESRD患者,使用TXA并未预示并发症显著增加,提示TXA不应在此人群中被视为禁忌。

研究设计与样本

  • 回顾性图表综述,纳入2011年1月至2024年2月共123例ESRD和/或透析患者。
  • 40例行择期初次全膝关节置换术(65%接受TXA),34例行择期初次全髋关节置换术(52.9%接受TXA),49例行非择期全髋关节置换术或半髋置换术(44.9%接受TXA)。

主要发现

  • 各TXA组间透析患者比例无差异:全膝关节置换术组65.4% vs 64.3%,全髋关节置换术组55.6% vs 50.0%,非择期或半髋置换术组86.4% vs 85.2%(P值均≥0.586)。
  • 全样本及各队列中,术前至术后(≤7天)肌酐变化及术后急性肾损伤发生率基于是否接受TXA无显著差异(P值均≥0.159)。
  • 接受TXA的患者中,肌酐变化基于剂量(P值均≥0.428)或给药途径(P值均≥0.256)无显著差异。
  • 90天急诊就诊、再入院或死亡率基于是否接受TXA无统计学显著差异(P值均≥0.055)。
  • 非择期或半髋置换术队列中,血栓栓塞事件发生4例(TXA组1例,非TXA组3例,P=0.617),围手术期输血发生2例(TXA组1例,非TXA组1例,P=0.882);择期队列中无上述事件。

临床怎么用

  • 作者认为,对因骨折接受全关节置换术或半髋置换术的ESRD患者,TXA不应被视为禁忌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) is a regally excreted antifibrinolytic commonly utilized in total joint arthroplasty (TJA). This study examined whether TXA administration affected clinical outcomes and kidney function in patients who had end-stage renal disease (ESRD) undergoing TJA or hemiarthroplasty (HA). METHODS: Through a retrospective chart review, we identified 123 patients: 40 who underwent primary elective total knee arthroplasty (TKA; 65% received TXA), 34 who underwent primary elective total hip arthroplasty (THA; 52.9% TXA), and 49 who underwent nonelective THA or HA (44.9% TXA) from January 2011 to February 2024. All patients had ESRD and/or were on dialysis, with no difference in percentage on dialysis between TXA groups (TKA: 65.4 versus 64.3%; THA: 55.6 versus 50.0%; non-elective or HA: 86.4 versus 85.2%, P values ≥ 0.586). Demographic and perioperative characteristics, including preoperative hemoglobin, TXA administration, dose, and route of administration (intravenous and topical), were extracted. Pre and postoperative (≤ seven days) creatinine, perioperative transfusions, revisions, and 90-day emergency department visits, readmissions, and mortalities were recorded and compared between TXA groups. RESULTS: In the total sample and all cohorts, change in pre to postoperative creatinine and incidence of postoperative acute kidney injury, per Kidney Disease Improving Global Outcomes guidelines, did not significantly differ based on receiving TXA (P values ≥ 0.159). Among patients receiving TXA, change in creatinine did not significantly differ by dose (P values ≥ 0.428) or route of administration (P values ≥ 0.256). There were no statistically significant differences in 90-day emergency department visits, readmissions, or mortalities based on receiving TXA (P values ≥ 0.055). Thromboembolic events occurred in four patients (one TXA and three no TXA, P = 0.617), and perioperative transfusions occurred in two patients (one TXA and one no TXA, P = 0.882) in the nonelective or HA cohort, with none in the elective cohorts. CONCLUSIONS: The administration of TXA does not portend a significant increase in complications for patients who have ESRD undergoing TJA or HA for fracture, suggesting TXA should not be contraindicated in this population.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Huebschmann NA, Esper GW, Robin JX, et al. Is Tranexamic Acid Safe for Patients Who Have End-Stage Renal Disease Undergoing Total Joint Arthroplasty? J Arthroplasty. 2024. PMID: 39551400. doi:10.1016/j.arth.2024.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。